The Wnt pathway is activated either by β-catenin exon 3 mutations in low-grade endometrioid carcinoma [7] or by overexpression of Dvl3 protein in high-grade endometrioid carcinoma. This evidence concerns the gene DVL3 and endometrioid adenocarcinoma.